TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models
The ruthenium-based photosensitizer (PS) TLD1433 has completed a phase I clinical trial for photodynamic therapy (PDT) treatment of bladder cancer. Here, we investigated a possible repurposing of this drug for treatment of conjunctival melanoma (CM). CM is a rare but often deadly ocular cancer. The...
Main Authors: | Quanchi Chen, Vadde Ramu, Yasmin Aydar, Arwin Groenewoud, Xue-Quan Zhou, Martine J. Jager, Houston Cole, Colin G. Cameron, Sherri A. McFarland, Sylvestre Bonnet, B. Ewa Snaar-Jagalska |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/3/587 |
Similar Items
-
TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro
by: Sarah Chamberlain, et al.
Published: (2020-06-01) -
Conjunctival Intraepithelial Neoplasia in a Patient Presenting with Pigmented Conjunctival Lesion
by: Winai Chaidaroon, et al.
Published: (2021-01-01) -
Autologous limbus conjunctival flap transplantation for pterygium accompaniedwith conjunctival cyst
by: Jin-Hua Wang, et al.
Published: (2017-06-01) -
Efficacy of conjunctival autograft transplant and limbal-conjunctival autograft transplant for primary pterygium
by: Yan Cai, et al.
Published: (2016-07-01) -
Bilateral conjunctival melanocytosis and retinitis pigmentosa
by: Rajesh Subhash Joshi, et al.
Published: (2019-01-01)